Total
0
Shares
Advanced Human Imaging (ASX:AHI) - Chairman and CEO, Vlado Bosanac
Chairman and CEO, Vlado Bosanac
Source: AHI
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Advanced Human Imaging (AHI) announces it will commence US presentations to raise US$15 million (nearly A$20 million)
  • The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission
  • AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS)
  • The filing is based on an assumed ratio of one ADS to nine ordinary shares of AHI
  • On the market today, AHI was down 10.3 per cent and is trading at $1.01 per share

Advanced Human Imaging (AHI) has announced it will commence US presentations to raise US$15 million (nearly A$20 million).

The health imaging company is aiming to list on the NASDAQ, after filing a Form F-1 with the US Securities and Exchange Commission.

AHI has now received conditional approval from the Nasdaq to list its American Depositary Shares (ADS), each of which will represent a determined number of ordinary shares of AHI.

Final approval of the listing is subject to the company paying the Nasdaq listing fee and fulfilling the remaining conditions as needed by Nasdaq.

Additionally, AHI has submitted an updated public filing of a registration statement on Form F-1, with the US Securities and Exchange Commission.

The updated filings is for the proposed initial US public offering of its ADS. The number of securities to be sold and the price per ADS for the offering have been outlined in the F-1, based on a price range of US$7 to US$9 (about A$9 to A$12).

The filing was based on an assumed ADS to ordinary share ratio of one (1) ADS representing nine (9) ordinary shares of AHI.

On the market today, AHI was down 10.7 per cent, trading at $1.00 per share at 1:20 pm AEDT.

AHI by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.